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Listeriolysin O (LLO), a cholesterol-binding cytolysin of Listeria monocytogenes, exhibits cytokine-inducing
and cytolytic activities. Because the cytolytic activity was abolished by cholesterol treatment but the cytokine-
inducing activity was not, these activities appeared to be linked to different domains of the LLO molecule. In
this study, we constructed recombinant full-length LLO (rLLO529) and various truncated derivatives and
examined their cytolytic, cholesterol-binding, and gamma interferon (IFN-)-inducing activities. rLLO529
exhibited both IFN--inducing and cytolytic activities. Four truncated rLLOs possessing different C termini,
which did not exert either cytolytic or cholesterol-binding activity, stimulated IFN- production in normal
spleen cells. However, a truncated rLLO corresponding to domain 4 (rLLO416–529) did not exhibit IFN--
inducing activity, whereas it did bind to immobilized cholesterol. In addition, though the hemolysis induced by
rLLO529 was inhibited by rLLO416–529, such inhibition was not detected upon rLLO529-induced IFN-
production. These data indicated that domain 4 was responsible for binding of LLO to membrane cholesterol
followed by oligomerization and pore formation by the entire LLO molecule. In contrast, the other part of LLO,
corresponding to domain 1–3, was essential for IFN--inducing activity. These findings implied a novel aspect
of the function of LLO as a bacterial modulin.
Listeria monocytogenes is a gram-positive, facultative intra-
cellular bacterium which is responsible for sporadic but severe
infections in humans and other animal species (18, 28). The
major virulence factor of this bacterium essential for intracel-
lular survival inside professional phagocytes is listeriolysin O
(LLO), a pore-forming cytolysin (15). Based on the loss of
escape from the phagosomal compartment into the cytosolic
space of macrophages in LLO-deficient mutants, LLO is be-
lieved to lyse the phagosomal membrane and enable L. mono-
cytogenes to gain access to the cytosol, resulting in intracellular
parasitism (6, 17, 25).
LLO has been purified from culture supernatant of L. mono-
cytogenes as a homogenous protein of approximately 60 kDa
(10, 14). The gene encoding LLO, hly, has been cloned and
sequenced, and the amino acid sequence of LLO has been
determined (8, 19). LLO is a member of the family of thiol-
activated cytolysins (TACYs), including streptolysin O (SLO),
pneumolysin (PLY), and perfringolysin O (PFO) (1). An im-
portant feature of the TACYs is the presence of a highly
conserved undecapeptide sequence (ECTGLAWEWWR) in
the C-terminal region that is believed to be essential for the
hemolytic activity. Conversion of the unique cysteine residue
located within the undecapeptide of SLO (24), PLY (27), and
LLO (20) to alanine by site-directed mutagenesis resulted in a
minor loss of activity. In addition, pyolysin, a TACY from
Arcanobacterium pyogenes, is reported to contain no cysteine
residue in the undecapeptide (5). In contrast, a drastic de-
crease in hemolytic activity was observed after replacement of
one of the three hydrophobic tryptophan residues in the un-
decapeptide of LLO, suggesting a critical role of the trypto-
phan residue(s) for the expression of its activity (20). A similar
result has been reported regarding the importance of trypto-
phan in the hemolytic activity of PFO (29).
Apart from the well-known cytolytic activity of LLO, we
have reported that LLO is a potent inducer for cytokines in
murine cells. Purified LLO was able to stimulate macrophages
to produce interleukin-1 (32) and induce various cytokines in
spleen cells in vitro (22). Though the hemolytic activity of LLO
is known to be blocked by cholesterol (16), its cytokine-induc-
ing ability was not affected by the cholesterol treatment (22,
34). It was suggested that the cytolytic activity of LLO could be
dissociated from its cytokine-inducing ability. In the present
study, to define the dissociation of hemolytic activity from
cytokine-inducing ability of LLO, we constructed recombinant
full-length LLO (rLLO) and various truncated LLOs. In a
previous study using purified native LLO, a striking production
of IFN- was observed (22), and it has been shown that IFN-
plays an important role especially in inducing protective im-
munity to L. monocytogenes (33). Therefore, we compared the
various rLLOs for cytolysis, cholesterol-binding and IFN- in-
duction.
MATERIALS AND METHODS
Extraction of chromosomal DNA from L. monocytogenes. Chromosomal DNA
was prepared according to the method of Flamm et al. (9). Briefly, L. monocy-
togenes strain EGD was grown overnight in 5 ml of brain heart infusion broth
(Difco Laboratories, Detroit, Mich.) and centrifuged at 15,000  g for 1 min.
Bacteria were washed with 0.1 SSC (0.015 M NaCl, 0.0015 M sodium citrate)
and suspended in 0.6 ml of lysozyme solution (2.5 mg of lysozyme per ml in 0.01
M sodium phosphate and 20% sucrose [pH 7.0]), followed by incubation for 1 h
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at 37°C. The mixture was added with 5.4 ml of proteinase K solution (500 g/ml
in 10 mM Tris-HCl [pH 8.0], 1 mM EDTA, and 1% sodium dodecyl sulfate) and
incubated for 1 h at 37°C. DNA was isolated by phenol-chloroform extraction
and ethanol precipitation and used as a template for PCR amplification of hly.
Construction and purification of mature and truncated LLOs. The hly gene,
encoding mature LLO, and the genes coding for various portions of LLO were
amplified by PCR with 5 primers containing BamHI sites (hly26, hly59, or
hly416) and 3 primers containing PstI sites (hly529, hly493, hly482, or hly415).
The sequences of forward and reverse primers used in this study are listed in
Table 1. The target DNA and amplified PCR fragments were sequenced with an
ABI Prism 310 genetic analyzer (Perkin-Elmer Applied Biosystems, Foster City,
Calif.) to confirm that mutations were not introduced during the course of PCR
amplification with a GeneAmp PCR system 9700 (Perkin-Elmer Applied Bio-
systems). The PCR fragments were digested with BamHI and PstI and ligated
into pQE-31 vectors (Qiagen, Tokyo, Japan) digested with the same enzymes.
Recombinant plasmid was electroporated into Escherichia coli SG13009, and
expression of six-His-tagged rLLOs was induced by incubation with 1 mM iso-
propyl--D-thiogalactopyranoside (Nacalai Tesque, Kyoto, Japan) at 25°C for 2
to 6 h. Cells were harvested by centrifugation at 6,000  g for 15 min, suspended
in lysis buffer (50 mM NaH2PO4 [pH 8.0], 300 mM NaCl, 20 mM imidazole, 1 mg
of lysozyme per ml, 200 U of DNase), and disrupted by vortexing with 0.1-mm
zirconia-silica beads. The soluble fraction was collected by centrifugation at
20,000  g for 30 min, and His-tagged rLLOs were purified with a nickel-
nitrilotriacetic acid column (Qiagen) according to the manufacturer’s instruc-
tions. Contaminating lipopolysaccharide (LPS) was extensively removed by using
Detoxi-Gel endotoxin-removing gel (Pierce Chemical Company, Rockford, Ill.).
The level of LPS was determined by a Limulus color KY test (Wako Pure
Chemical Industries, Osaka, Japan). Protein concentration was measured with a
protein assay reagent (Nacalai), and purity was determined by Coomassie blue
staining and Western blotting after sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). A monoclonal anti-His tag antibody (penta·His
antibody; Qiagen) and a polyclonal anti-LLO antibody raised in rabbits by
repeated immunization with purified LLO from culture supernatant of L. mono-
cytogenes were used for Western blot analysis.
Hemolytic and cytolytic activities of rLLOs. The hemolytic activity of rLLOs
was determined by the level of hemoglobin released from 0.5% sheep red blood
cells (SRBC). Briefly, various concentrations of rLLOs that had been treated
with 10 g of cholesterol per ml or left untreated were incubated with 0.5%
SRBC in a total volume of 100 l of phosphate-buffered saline (PBS) at 37°C for
30 min. After centrifugation at 800  g for 10 min, the supernatant was collected
and the absorbance of hemoglobin at 415 nm was measured. One hemolytic unit
was defined as the amount of rLLOs that caused 50% hemoglobin release from
100 l of 0.5% SRBC. In some experiments, SRBC were treated with rLLO416–
529, corresponding to domain 4 of LLO, at 37°C for 1 h and hemolysis of the
pretreated SRBC by full-length rLLO was examined.
The cytolytic activity was also determined by measuring the level of lactate
dehydrogenase (LDH) released from macrophage-like cell line J774.1. Cells
were suspended in culture medium consisting of RPMI 1640 medium (Gibco
BRL, Life Technologies, Inc., Rockville, Md.) supplemented with 10% (vol/vol)
heat-inactivated fetal bovine serum (Gibco) and 5 g of gentamicin per ml and
plated at 1.0  105 cells per well in a 48-well flat-bottomed tissue culture plate.
After incubation at 37°C overnight, cells were washed and incubated with various
doses of rLLOs for 6 h. The culture supernatant was collected, and the level of
LDH was measured with an LDH cytotoxicity detection kit (Takara Shuzo Co.,
Shiga, Japan). In order to confirm that binding of LLO to membrane cholesterol
was essential for the cytolytic activity, full-length rLLO was treated with 10 g of
free cholesterol per ml and the cytotoxicity was assayed.
Binding activity of rLLOs to cholesterol. Various amounts of cholesterol were
spotted on a thin-layer chromatography (TLC) sheet (Polygram Sil G; Macherey-
Nagel, Düren, Germany). The sheet was dried, soaked overnight at 4°C in buffer
A, consisting of 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, and 25% Block Ace
(Dainippon Pharmaceutical Co., Osaka, Japan), and incubated with 100 nM
rLLOs dissolved in buffer A for 1 h at room temperature with constant agitation.
The sheet was washed six times with buffer A and incubated with a monoclonal
anti-His tag antibody for 1 h, followed by further incubation for 1 h with horse-
radish peroxidase (HRP)–rabbit anti-mouse immunoglobulin G (IgG) (Zymed
Laboratories Inc., San Francisco, Calif.). The sheet was washed six times, and
spots were detected with a peroxidase stain kit for immunoblotting (Nacalai). In
some experiments, in order to determine whether rLLO416–529 (domain 4)
inhibits the binding of rLLO529 to cholesterol, the TLC sheet that was spotted
with cholesterol (0.06 g) was treated with various concentrations of rLLO416–
529 for 1 h at room temperature with constant agitation. After several washes,
the sheet was incubated with 50 nM rLLO529 for 15 min. Silica gel in an area
where cholesterol was spotted was scraped off from the sheet and boiled in
SDS-PAGE sample buffer, and the supernatant was subjected to Western blot-
ting. In order to quantitatively detect the binding activity, the assay was carried
out with a polyvinylidene difluoride (PVDF) membrane instead of the TLC sheet
(2). Briefly, various concentrations of cholesterol dissolved in chloroform-etha-
nol (1:1) solution were plated in a 96-well filtration plate that had an Immo-
bilon-P membrane (Millipore, Bedford, Mass.) at the bottom and allowed to dry
overnight. The cholesterol-coated wells were treated with blocking buffer con-
sisting of 4% heat-inactivated fetal bovine serum in PBS for 1 h, and 100 l of
2 nM rLLOs in blocking buffer was added to each well. After 1 h of incubation,
wells were washed four times with blocking buffer and sequentially treated with
monoclonal anti-His tag antibody and HRP–rabbit anti-mouse IgG. rLLO bound
to cholesterol was quantified by the addition of 100 l of 3,3,5,5-tetramethyl-
benzidine (TMB) in phosphate-citrate buffer (pH 5.0) containing 0.01% H2O2
and measurement of the absorbance at 450 nm after termination of the reaction
with 100 l of 0.18 M H2SO4.
Production of IFN- induced by rLLOs. C3H/HeN mice were used for exper-
iments at 7 to 9 weeks of age. Normal spleen cells were plated at 2.5  106 per
well in a 48-well flat-bottomed tissue culture plate and stimulated with 100 l of
various concentrations of rLLOs for 24 h. In some experiment, spleen cells were
first treated with various concentrations of rLLO416–529 for 1 h on ice and then
stimulated with 50 nM rLLO529 for 24 h. The culture supernatant was collected,
and the level of IFN- was measured by enzyme immunoassay as follows. The
supernatants and IFN- standard were plated in the wells of a Nunc immuno-
plate (Nalge Nunc Int., Tokyo, Japan) which had been coated with 1.5 g of rat
anti-mouse IFN- antibody (Endogen, Woburn, Mass.) per ml and treated with
25% Block Ace to inhibit nonspecific binding. The plate was incubated for 1 h,
washed with PBS containing 0.1% Tween 20, and sequentially incubated with
biotin-conjugated anti-mouse IFN- monoclonal antibody (Endogen) and HRP-
conjugated streptavidin (Endogen). IFN- was detected by the addition of 50 g
of TMB per ml in phosphate-citrate buffer (pH 5.0) containing 0.01% H2O2 and
measurement of the absorbance at 450 nm after the addition of 0.18 M H2SO4.
Statistical analysis. All assays for hemolytic, cytolytic, cholesterol-binding, and
IFN--inducing activities were independently repeated three times, and similar
results were obtained. Representative data were expressed as means  standard
deviations of triplicate determinations. Statistical significance was analyzed by
Student’s t test.
RESULTS
Construction of rLLOs. Based on the DNA sequence of hly,
coding for LLO (19), various rLLOs were constructed. In ad-
dition to the full-length LLO without a signal sequence
(rLLO529), we constructed three rLLOs with the C terminus
truncated (rLLO493, rLLO482, and rLLO415), one with the N
terminus truncated (rLLO416–529), and one with both termini
truncated (rLLO59–415) (Fig. 1). Mature LLO obtained from
culture supernatant of L. monocytogenes was 504 amino acids
in length, with a molecular mass of 55.8 kDa (19). Because
rLLO529 contains six histidines at the N terminus and an extra
10 amino acids encoded by the DNA sequence of the vector,
the predicted molecular mass was 56.7 kDa. The size of puri-
TABLE 1. Oligonucleotide primers used in this study
Primer Nucleotide sequence (5-3)a
Forward
hly26....................CGATGGATCCTGATGCATCTGCATTCAATAAAG
hly416..................CGATGGATCCTGATGGAAAAATTAACATCGA
hly59....................CGATGGATCCTGATGAAATCGATAAGTATATAC
Reverse
hly529..................ACGCCTGCAGTTCGATTGGATTATCTACACTATTAC
hly493..................ACGCCTGCAGTCTCCACCATTCCCAAGCT
hly482..................ACGCCTGCAGTTTAGCGTAAACATTAATATTTC
hly415..................ACGCCTGCAGTGTATAAGCTTTTGAAGTTGT
a The added restriction sites are underlined (BamHI for forward primers, PstI
for reverse primers).
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fied rLLO529 on an SDS-PAGE gel was in agreement with this
value (Fig. 2A). Each rLLO could also be observed at the
position corresponding to each predicted molecular mass as a
single band on SDS-PAGE gels (Fig. 2A) and immunoblots
(Fig. 2B).
Hemolytic activity of rLLOs. The hemolysis induced by
rLLO529 was dose dependent, and the maximum activity was
detectable at as low as 1 nM (Fig. 3A). The hemolytic activity
of rLLO529 was calculated to be about 18,000 hemolytic
units/mg of protein (Fig. 3B) and was almost completely in-
hibited by pretreatment with cholesterol (Fig. 3A). At higher
concentrations (100 and 200 nM), however, the hemolysis was
markedly decreased but not completely inhibited by treatment
with cholesterol. This appeared to be due to the insufficient
amount of cholesterol to block the hemolytic activity, since
there was a limit of the solubility of cholesterol in an aqueous
phase. In contrast to rLLO529, no truncated rLLOs exhibited
detectable hemolytic activity. These data indicated that the
C-terminal portion of LLO was essential in the hemolytic pro-
cess, whereas pore formation does not take place by domain 4
of LLO (rLLO416–529) alone.
Cholesterol-binding activity of rLLOs. The cholesterol-bind-
ing activity of rLLOs was determined by the level of rLLOs bound
to cholesterol immobilized on a PVDF membrane or a TLC
sheet. rLLO529 had a significant level of cholesterol-binding
activity. The binding increased depending on the dose of cho-
lesterol and reached the maximum at 0.5 g of cholesterol
(Fig. 4A). Treatment of rLLO529 with free cholesterol abol-
ished the binding to immobilized cholesterol. In contrast, all
the rLLOs truncated at the C terminus (rLLO493, rLLO482,
rLLO415, and rLLO59–415) exhibited no cholesterol-binding
activity (Fig. 4B). A similar result was obtained in the experi-
ment using a TLC sheet (Fig. 4C). Cholesterol-binding activity
was exhibited by rLLO416–529, a truncated protein corre-
sponding to domain 4 of LLO, though its activity was some-
what lower than that of rLLO529 (Fig. 4B and C). These data
indicated that the C-terminal portion of LLO was critical for
cholesterol binding and that there was a significant correlation
FIG. 1. Construction of various rLLOs. The amino acid sequence is
numbered from the N terminus. Gray bars represent polypeptide re-
gions of full-length and truncated LLOs. The filled box in the LLO
structure represents a region of the undecapeptide (ECTGLAWEWWR;
residues 483 to 493) which is common among thiol-activated cytolysins.
FIG. 2. SDS-PAGE and Western blot analysis for the purity of
rLLOs. The purified rLLOs were subjected to SDS-PAGE with a 10 to
20% gradient gel. (A) The gel was stained with Coomassie brilliant
blue. (B) The proteins were electroblotted to a PVDF membrane, and
Western blotting was performed with anti-His tag antibody. The posi-
tions of molecular mass standards are indicated on the left. Lanes: A,
rLLO529; B, rLLO493; C, rLLO482; D, rLLO415; E, rLLO59–415; F,
rLLO416–529
FIG. 3. Cholesterol-dependent hemolysis induced by rLLO529 and
comparison of hemolytic activity among rLLOs. (A) rLLO529 (1,000
nM) was serially diluted twofold with PBS and treated with cholesterol
(10 g/ml) or left untreated. Four volumes of SRBC suspension was
added to make a final concentration of 0.5%, and the suspension was
incubated for 30 min at 37°C. Hemolysis was measured by release of
hemoglobin in the supernatant. (B) Hemolysis caused by rLLOs was
measured as described above. HU, hemolytic units.
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between the binding activity to cholesterol and hemolytic ac-
tivity.
Cytotoxicity of rLLOs for macrophage. Cytotoxicity of rLLOs
for macrophage-like cell line J774.1 was determined by mea-
suring the release of LDH. J774.1 cells were incubated with
various concentrations of rLLO529 that had been treated with
cholesterol or left untreated, and the culture supernatant was
collected 6 h after incubation. As was the case with the hemo-
lytic activity, rLLO529 exhibited a dose-dependent cytotoxicity
to J774.1 cells and the activity was almost completely blocked
by pretreatment with cholesterol (Fig. 5). At doses over 50 nM,
however, the activity was diminished but not completely inhib-
ited by the cholesterol treatment, indicating the insufficient
blockade of the cytotoxicity by cholesterol as seen with the
hemolytic activity of rLLO529. The cytotoxicity of truncated
rLLOs for J774.1 cells was similar to that for hemolysis (data
not shown).
IFN--inducing ability of rLLOs. Normal spleen cells were
stimulated for 24 h with rLLO529 that had been treated with or
without cholesterol, then the level of IFN- was assayed by
ELISA. IFN- production was not observed in cells incubated
with rLLO529 that had not been cholesterol treated. In con-
trast, cholesterol-treated rLLO529 was capable of inducing
IFN- production at 50 nM (Fig. 6A). At over 50 nM, however,
rLLO529 did not induce IFN- production. The absence of
IFN--inducing activity at higher concentrations appeared to
be due to the cytotoxicity remaining even after treatment with
cholesterol (Fig. 5).
In order to rule out the possible involvement of contaminat-
ing LPS in IFN- induction, recombinant proteins were passed
extensively through an LPS-removing column. The amount of
LPS in the working concentration of rLLO preparations was at
most 10 pg/ml. As shown in Fig. 6B, IFN- production was not
induced even with 100 pg of LPS per ml, a dose 10 times higher
than that in rLLO samples. In addition, the IFN--inducing
activity was not affected by polymyxin B, whereas the response
to 1 ng of LPS per ml was completely inhibited by the same
treatment. Furthermore, we found that IFN- production in-
duced by rLLO529 was abolished by anti-LLO polyclonal an-
tibody. These data clearly showed that rLLO itself was able to
stimulate spleen cells to produce IFN-.
Based on the fact that cytokine-inducing activity of rLLO529
was expressed only when its cytotoxicity was abolished, there
was a possibility that two different activities were linked to
different domains of the LLO molecule. To address this pos-
sibility, we tested the IFN--inducing activity of rLLO prepa-
rations with the C-terminal truncation that lacked the cytotoxic
activity. Full-length LLO (rLLO529) induced IFN- produc-
tion at 50 nM, but not at the doses exhibiting cytotoxicity (Fig.
7). On the other hand, rLLO493 was capable of inducing
FIG. 4. Binding of rLLOs to immobilized cholesterol. (A) Different
amounts of cholesterol were plated in 96-well microtiter plates with
PVDF membranes at the bottom. Cholesterol-treated or untreated
rLLO529 (2 nM) was added, and the wells were incubated with anti-
His tag antibody followed by HRP-conjugated anti-mouse IgG.
rLLO529 bound to immobilized cholesterol was detected by the addi-
tion of TMB to the wells. (B) Cholesterol (0.5 g) was plated in the
PVDF membrane-containing 96-well plates. Recombinant LLOs were
adjusted at 2 nM, and the binding activities to cholesterol were deter-
mined. (C) Various concentrations of cholesterol were spotted on TLC
plates. TLC plates were incubated with 100 nM rLLOs and then
incubated with monoclonal anti-His tag antibody followed by HRP-
conjugated anti-mouse IgG. Binding of rLLOs to cholesterol was de-
tected by peroxidase staining.
FIG. 5. Cytotoxicity of rLLO529 for J774.1 cells. J774.1 cells (105
cells) were cultured overnight in 48-well plate. The supernatant was
removed, and various concentrations of rLLO529 were added with or
without cholesterol treatment. LDH released in the supernatant was
measured 6 h after addition of rLLO529 to the cells.
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IFN- production at doses as high as 200 nM. The level of
IFN- induced by 100 to 200 nM rLLO493 was significantly
higher than that detected at 50 nM. This suggested that opti-
mal dose of rLLO529 and truncated rLLOs for IFN- produc-
tion was higher than 50 nM, at which the cytotoxicity could be
inhibited by cholesterol treatment. As expected, a high level of
IFN- production was also induced upon stimulation with
rLLO482, rLLO415, and rLLO59–415 at higher doses, while
we could not compare the activity at all concentrations because
the highest available concentration was limited in some prep-
arations. In contrast with these rLLOs, rLLO416–529 was not
able to induce IFN- production even at 1,000 nM, suggesting
that domain 4 of LLO is critically involved in hemolytic activity
but not in IFN--inducing activity. Based on these results, it
was likely that the cytokine-inducing ability of LLO was linked
to domain 1–3 and domain 4 was not required. However,
rLLO529 showed IFN--inducing activity at 50 nM, whereas
rLLO415 did not. It was suggested that domain 4 plays some
role in facilitating IFN- induction by the whole molecule.
Involvement of domain 4 in hemolysis but not in IFN-
production induced by full-length LLO. In order to confirm
the dissociation between hemolysis and IFN- production in-
duced by rLLO529 on a molecular basis, we have examined
whether rLLO416–529 (domain 4) inhibits IFN- induction
and hemolysis caused by rLLO529. SRBC were treated with
rLLO416–529 and subjected to hemolysis assay as the target
cells. When SRBC were pretreated with an excess amount of
rLLO416–529, there was a decrease in the level of hemolysis
caused by rLLO529 (Fig. 8), indicating that rLLO416–529 was
able to block the hemolytic process. In contrast, IFN- pro-
duction induced by 50 nM rLLO529 was not inhibited even
when cells were treated with 1,000 nM rLLO416–529. This
result indicated that the binding of rLLO529 to cells via do-
main 4 was not required for the induction of IFN- production
(Fig. 8). Next, we examined whether the inhibition of hemoly-
sis by rLLO416–529 was due to the inhibition of the binding of
rLLO529 to cholesterol. A TLC sheet that had been spotted
with cholesterol was first treated with rLLO416–529 at differ-
ent concentrations. After several washes, the sheet was incu-
bated with rLLO529 and the binding of rLLO529 to choles-
terol was determined by immunoblotting. The amount of
rLLO529 bound to cholesterol was shown to decrease with
increasing doses of rLLO416–529 (Fig. 9). The binding of
rLLO529 (50 nM) was markedly inhibited when the sheet was
pretreated with 1,000 nM rLLO416–529 and hardly detected
upon pretreatment with 2,000 nM domain 4, indicating that
FIG. 6. IFN- production by normal spleen cells stimulated with
rLLO529. (A) Normal spleen cells were stimulated for 24 h with
various concentrations of rLLO529 which had been treated with cho-
lesterol or left untreated. The supernatant was collected and the level
of IFN- was measured by enzyme-linked immunosorbent assay.
(B) Normal spleen cells were stimulated with 50 nM cholesterol-
treated rLLO529 or LPS (0.1 and 1 ng/ml) in the presence or absence
of polymyxin B (PMB; 0.5 g/ml) and anti-LLO antibody (Ab) (1
g/ml) for 24 h.
FIG. 7. IFN--inducing activity of rLLO529 and five truncated
LLOs. Normal spleen cells were stimulated with various concentra-
tions of cholesterol-treated rLLOs for 24 h, and the level of IFN-
production was determined. ND, not done.
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rLLO416–529 competitively inhibited the binding of rLLO529
to cholesterol.
DISCUSSION
LLO, a 58-kDa cytolytic protein toxin produced by the in-
tracellular pathogen L. monocytogenes, belongs to a family of
TACYs (13). PFO produced by Clostridium perfringens is a
member of this family. Recently, the three-dimensional struc-
ture of PFO was determined to consist of four domains, in-
cluding the continuous domain 1–3, involved in polymeriza-
tion, and domain 4, harboring the membrane-binding portion
of the cytolysin (26). The Trp-rich undecapeptide conserved in
all TACYs is present in domain 4 in the C-terminal region and
is thought to be involved in the formation of a hydrophobic
pocket that renders TACYs capable of binding cholesterol (1).
Because of the high homology at both DNA and amino acid
sequence levels among various TACYs, LLO appears to have
a domain structure similar to that of PFO (13).
In contrast to the well-established cytolytic activity of LLO,
the ability to induce host cytokine, which we have reported (22,
33), is a completely different biological activity of LLO. In the
present study, the structural requirements of the LLO mole-
cule for cytolytic and cytokine-inducing abilities were com-
pared. For that purpose, we constructed various rLLO prepa-
rations with truncations (Fig. 1 and 2). The full-length LLO
(rLLO529) exhibited a hemolytic activity at a concentration as
low as 1 nM against SRBC, and hemolysis was abolished by
treatment with cholesterol up to 50 nM (Fig. 3). rLLO529 also
showed a similar pattern of cytolytic activity against J774.1
cells, and significant activity was detected at the concentration
above 12.5 nM (Fig. 5). No recombinants with truncations at
the N and/or C termini exhibited hemolytic activity regardless
of the presence or absence of the Trp-rich undecapeptide
(residues 483 to 493). Binding to cholesterol was abolished in
all four preparations truncated at the C terminus, in which one
possessed the undecapeptide and three did not. In contrast,
rLLO416–529, representing domain 4, was able to bind to
cholesterol (Fig. 4). It was suggested that the intact structure of
domain 4 was required for binding to membrane cholesterol,
resulting in pore formation, and that the presence of the Trp-
rich undecapeptide is not sufficient. This result was consistent
with the findings that C-terminal truncation of PFO (30) and
PLY (3, 23) resulted in the loss of erythrocyte-binding activity
even if the Trp-rich undecapeptide is present. The dissociation
between membrane binding and hemolysis of LLO was also
reported in a study using monoclonal antibodies directed
against different epitopes of LLO (7). The cytolytic process
consists of at least four steps: binding to cholesterol in mem-
branes, insertion into the membrane, oligomerization, and
eventual pore formation (4). The present results suggested that
truncation of the C terminus in LLO mainly affects the binding
via membrane cholesterol.
The main purpose of the present study was to examine
whether there is any difference in the structural dependency
between the cytolytic activity and the cytokine-inducing ability
of LLO. IFN- was produced after stimulation of spleen cells
with the full-length rLLO529 only after treatment with free
cholesterol and not with untreated preparation (Fig. 6). The
increase in the concentration for stimulation resulted in a
decrease in the amount of IFN- produced. At the concentra-
tion of rLLO529 optimal for cytokine induction (50 nM), the
truncated proteins appeared to have lost the IFN--inducing
ability; however, rLLO493, rLLO482, rLLO415, and rLLO59–
415 were all active in cytokine induction when applied at
higher concentrations (Fig. 7). It was interesting that cytokine-
inducing activity of these truncated preparations was expressed
without blocking with free cholesterol, since they have com-
pletely lost the cholesterol-binding and cytolytic activity. From
the results obtained in the LDH release assay, it was clear that
truncation eliminated the damage to the macrophage mem-
brane (data not shown). It was possible that the remaining
cytolytic activity which was not completely abolished by cho-
FIG. 8. Inhibitory effect of rLLO416–529 (domain 4) on hemolytic
activity but not on IFN--inducing activity of rLLO529. Normal spleen
cells were treated with various concentrations of rLLO416–529 for 1 h
at 4°C and were stimulated with 50 nM cholesterol-treated rLLO529
for 24 at 37°C. The supernatant was collected, and the IFN- in the
supernatant was measured. SRBC (1%) were treated with various
concentrations of rLLO416–529 for 1 h at 4°C. rLLO529 was added to
the SRBC suspension at 50 nM, and the mixture was incubated for 30
min at 37°C. The hemolysis caused by rLLO529 was determined. The
inhibitory activity of rLLO416–529 for IFN- production and hemoly-
sis was expressed as percent decrease of activity in the presence of
rLLO416–529.
FIG. 9. Inhibitory effect of rLLO416–529 on the binding of
rLLO529 to cholesterol. Cholesterol (0.06 g) was spotted on a TLC
sheet. The sheet was treated with 0 (lane 1), 500 (lane 2), 1,000 (lane
3), and 2,000 (lane 4) nM rLLO416–529 for 1 h. After several washes,
the sheet was incubated with 50 nM rLLO529 for 15 min. Silica gel was
scraped off, and bound rLLO416–529 and rLLO529 were detected by
Western blotting using anti-His tag antibody.
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lesterol treatment affected the cytokine induction by rLLO529
due to the limitation in the amount of cholesterol to be solu-
bilized in aqueous phase.
The most significant level of cytokine induction, much
higher than that by full-length rLLO, was observed with
rLLO415, in which the cholesterol-binding domain was com-
pletely eliminated (Fig. 7). This preparation corresponds to
domain 1–3 of LLO according to the comparison of amino acid
sequence to that of PFO; therefore, this result implied that
domain 1–3 is fully capable of inducing the cytokine response.
The possibility that the LPS contaminating the sample was
responsible for the quite high activity of rLLO415 should be
ruled out. Treatment of this sample with polymyxin B at a dose
of 0.5 g/ml did not affect the activity. The level of LPS de-
termined by Limulus assay never exceeded 10 pg/ml, which was
not effective in the induction of this high level of IFN- in
spleen cell culture. Moreover, IFN- production was abolished
by anti-LLO antibody. From these observations, the results
shown in Fig. 7 can be regarded as the activity of recombinant
protein itself, not an artifact of contaminating LPS.
From the results presented here, it can be concluded that
cholesterol-binding activity is not required for the expression
of cytokine-inducing activity of LLO. Domain 1–3 appeared to
be highly potent in the induction of IFN- production by naive
spleen cells of mice, but there may be a contribution from
domain 4 or the overall molecular structure consisting of do-
mains 1 through 4 to the expression of cytokine-inducing ac-
tivity in the full-length molecule, because rLLO truncated at
the C terminus did not induce IFN- production at 50 nM
whereas rLLO529 showed activity at the same dose. In a study
using PFO, it was shown that treatment with cholesterol in-
duces a conformational change of PFO (21). There is a possi-
bility that the interaction of LLO with cholesterol in solution
resulted in a conformational change of the LLO molecule,
which leads LLO to exhibit high affinity for a putative receptor
for cytokine production. Though it may be argued that binding
of molecule to membrane cholesterol is not a prerequisite for
cytokine induction, the mechanism of signal transduction re-
sulting in IFN- induction remains to be elucidated. In a pre-
vious study, the production of IFN- in spleen cells after stim-
ulation with native LLO was dependent on macrophages, and
NK cells were the final source of IFN- (22). It was suggested
that signaling for cytokine induction is initiated through the
binding of LLO to some binding site or receptor molecule
other than membrane cholesterol on macrophages. This as-
sumption is in agreement with a report that pretreatment with
cholesterol did not influence the binding of native LLO to
erythrocytes and B lymphoma cell lines (12). As shown in Fig.
4, domain 4 is responsible for binding to cholesterol leading to
cytolysis. The fact that rLLO415 was capable of inducing
IFN- suggested the existence of a portion binding to a puta-
tive noncholesterol receptor. In this regard, the establishment
of rLLO415 lacking the cytotoxicity may be useful in the anal-
ysis of signal transduction after LLO-macrophage interaction
without interference by cytolytic activity. In addition, we have
shown that native LLO was highly active as an adjuvant in the
induction of Th1-dependent protective immunity against L.
monocytogenes after immunization with a non-LLO-producing
strain of L. monocytogenes when it was used after encapsula-
tion into the cholesterol-lecithin liposome (31). Because of the
absence of toxicity and the presence of enhanced cytokine-
inducing ability in truncated LLO, it will also be interesting to
apply this preparation to in vivo immunization, and such ex-
periments are under way. In conclusion, the present results
suggest a novel function of LLO as one of the cytokine-induc-
ing bacterial modulins (11), which is dissociable from its well-
established function as a membrane lytic protein toxin of L.
monocytogenes.
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